lifileucel 72,000,000,000 CELLS per 125 ML Injection
- RxCUI
- 2675868
- RxNorm name
- lifileucel 72,000,000,000 CELLS per 125 ML Injection
- Display name
- lifileucel 72,000,000,000 CELLS per 125 ML Injection
- Full name
- lifileucel 72,000,000,000 CELLS per 125 ML Injection
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:55
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125773 | AMTAGVI | Lifileucel | 351(a) | Rx | 2026-09-01 |
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| AMTAGVI | LIFILEUCEL | Iovance Biotherapeutics Inc. | 4121bd3f-2d6e-3bdd-e063-6294a90a3088 | 2025-10-14 | Boxed warning, Warnings, Adverse reactions | 2675868 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 4121bd3f-2d6e-3bdd-e063-6294a90a3088 | lifileucel 72,000,000,000 CELLS in 125 ML Injection [PSN] · 125 ML lifileucel 576000000 CELLS/ML Injection [SCD] · lifileucel 72,000,000,000 CELLS per 125 ML Injection [SY] | 3 | 4 | These highlights do not include all the information needed to use AMTAGVI safely and effectively. See full prescribing information for AMTAGVI. AMTAGVI (lifileucel) suspension for intravenous infusion Initial U.S. Approval: 2024 | 20251014 |
| 91b0c63a-9a7e-46d0-a562-dc0d7d7867f3 | lifileucel 72,000,000,000 CELLS in 125 ML Injection [PSN] · 125 ML lifileucel 576000000 CELLS/ML Injection [SCD] · lifileucel 72,000,000,000 CELLS per 125 ML Injection [SY] | 3 | 3 | These highlights do not include all the information needed to use AMTAGVI safely and effectively. See full prescribing information for AMTAGVI. AMTAGVI (lifileucel) suspension for intravenous infusion Initial U.S. Approval: 2024 | 20250919 |